Fung Yee Chan, MD
Obstetrics/Gynecology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 27 years
- Albert Einstein College of Medicine of Yeshiva University, 1999
Offices
1 location · Pacific Womens Obstetrics and Gynecology Medical Group Inc · 7 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chan’s office at (415) 379-9794 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A82699 · Current
Licensed to practise in California · since 2003 · expires 2027-01-31 · Albert Einstein College of Medicine of Yeshiva University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$2,307
Medicare paid this office $2,307 for 19 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 13 | $616 | $47 |
Who their Medicare patients are
19 Original Medicare patients in 2024. Average age 67 · Women 100% · Health risk score 0.55. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
The office billed $4,708, Medicare allowed $2,898 and paid $2,307; for 35 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 19 | 35 | 67 | 0.55 | $4,708 | $2,307 |
| 2023 | 21 | 52 | 70 | 0.51 | $7,812 | $2,721 |
| 2022 | 22 | 42 | 71 | 0.55 | $7,447 | $2,395 |
| 2021 | 14 | 24 | 70 | 0.78 | $2,682 | $1,275 |
| 2019 | 17 | 41 | 70 | 0.65 | $5,180 | $2,216 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $656 | $55 |
| Stool analysis for blood to screen for colon tumors | 12 | $51 | $4 |
2022: 2 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 14 | $742 | $53 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 16 | $740 | $46 |
2019: 2 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $583 | $53 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 12 | $551 | $46 |
Drugs they prescribed that Part D paid
$7,685
Pharmacies billed $7,685 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 57) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
39 generic and 18 brand-name prescriptions · $7,685 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prempro | 13 | $2,955 | $227 |
| Estradiol (Twice Weekly) | 11 | $815 | $74 |
| Estradiol | 11 | $513 | $47 |
Year by year
| 2024 | 57 | 14 | 0% (0) | 32% | $7,685 |
| 2023 | 37 | 12 | 0% (0) | 51% | $4,471 |
| 2022 | 29 | 12 | 0% (0) | 55% | $3,522 |
| 2021 | 30 | 13 | None | 57% | $4,099 |
| 2020 | 22 | None | 0% (0) | 50% | $4,072 |
| 2019 | 14 | None | 0% (0) | None | $2,099 |
| 2016 | 22 | None | 0% (0) | 64% | $1,389 |
| 2015 | 13 | None | 0% (0) | None | $829 |
| 2014 | 13 | None | None | None | $2,958 |
| 2013 | 15 | None | 0% (0) | None | $685 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Prempro | 13 | $2,945 | $227 |
2021: 1 drug
| Prempro | 11 | $2,272 | $207 |
Money from drug and device companies
$438 in 2025
| 2025 | 11 | 21 | None | $438 |
| 2024 | 16 | 23 | None | $847 |
| 2023 | 10 | 15 | None | $558 |
| 2022 | 9 | 22 | None | $477 |
| 2021 | 6 | 7 | None | $138 |
| 2019 | 2 | 4 | None | $109 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biogen | Zurzuvae | $78 | 3 payments
|
| Astellas Pharma US | Veozah | $74 | 3 payments
|
| Amgen | Evenity | $54 | 2 payments
|
| Millicent US | Femring | $37 | 2 payments
|
| Mayne Pharma Commercial | None | $36 | 4 payments
|
| CooperSurgical | Paragard T 380a | $32 | 2 payments
|
See all 21 published payments
| Astellas Pharma US | Meals · 2025-12-15 | Veozah | $33 |
| Mayne Pharma Commercial | Meals · 2025-11-17 | None | $3 |
| Amgen | Meals · 2025-10-15 | Evenity | $24 |
| Mayne Pharma Commercial | Meals · 2025-10-13 | None | $5 |
| CooperSurgical | Meals · 2025-10-04 | Paragard T 380a | $17 |
| Mayne Pharma Commercial | Meals · 2025-09-15 | None | $22 |
| Shield Therapeutics | Meals · 2025-08-18 | Accrufer | $29 |
| Pfizer | Meals · 2025-08-03 | Abrysvo | $20 |
| Exeltis USA | Meals · 2025-07-21 | Slynd | $25 |
| Mayne Pharma Commercial | Meals · 2025-07-07 | None | $6 |
| Biogen | Meals · 2025-06-30 | Zurzuvae | $29 |
| Biogen | Meals · 2025-05-30 | Zurzuvae | $24 |
| Biogen | Meals · 2025-04-07 | Zurzuvae | $25 |
| Vertex Pharmaceuticals | Meals · 2025-03-27 | Journavx | $31 |
| Meditrina | Meals · 2025-03-19 | None | $21 |
| Astellas Pharma US | Meals · 2025-03-12 | Veozah | $19 |
| Millicent US | Meals · 2025-03-11 | Femring | $21 |
| Millicent US | Meals · 2025-02-21 | Femring | $17 |
| CooperSurgical | Meals · 2025-02-12 | Paragard T 380a | $15 |
| Amgen | Meals · 2025-01-24 | Evenity | $29 |
| Astellas Pharma US | Meals · 2025-01-15 | Veozah | $22 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $847
| Astellas Pharma US | Veozah | $284 | 3 payments
|
| Hologic Sales and Service | Acessa Provu System | $169 | 2 payments
|
| Millicent US | Femring | $63 | 3 payments
|
| Lilly USA | Jardiance | $44 | 2 payments
|
| Biogen | None | $40 | 2 payments
|
| Vertex Pharmaceuticals | None | $33 | 1 payment
|
| Sanofi Pasteur | Beyfortus | $31 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $29 | 1 payment
|
| Ascend Therapeutics US | Estrogel | $25 | 1 payment
|
| Pfizer | Abrysvo | $24 | 1 payment
|
| Evofem Biosciences | None | $22 | 1 payment
|
| Amgen | Evenity | $22 | 1 payment
|
| Organon | Nexplanon | $21 | 1 payment
|
| Minerva Surgical | None | $21 | 1 payment
|
| Meditrina | None | $17 | 1 payment
|
| Mayne Pharma Commercial | None | $3 | 1 payment
|
2023: $558
| Ethicon US | Harmonic | $131 | 1 payment
|
| Hologic Sales and Service | Acessa Provu System | $114 | 2 payments
|
| Amgen | Evenity | $81 | 3 payments
|
| Mayne Pharma Commercial | None | $63 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $46 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $33 | 1 payment
|
| AbbVie | Orilissa | $26 | 1 payment
|
| Minerva Surgical | None | $23 | 1 payment
|
| Shield Therapeutics | Accrufer | $21 | 1 payment
|
| Ascend Therapeutics US | Estrogel | $19 | 1 payment
|
2022: $477
| Abbvie | Lo Loestrin Fe | $157 | 8 payments
|
| Mayne Pharma | None | $78 | 4 payments
|
| Hologic | Thinprep 2000 Processor | $63 | 2 payments
|
| TherapeuticsMD | Annovera | $47 | 2 payments
|
| Evofem Biosciences | Phexxi | $37 | 2 payments
|
| Medicem | Dilapan-S | $28 | 1 payment
|
| Sage Therapeutics | Zulresso | $25 | 1 payment
|
| Scynexis | None | $24 | 1 payment
|
| CooperSurgical | Paragard | $17 | 1 payment
|
2021: $138
| Evofem Biosciences | Phexxi | $42 | 2 payments
|
| Ethicon US | Surgicel Nu-Knit | $26 | 1 payment
|
| Myovant Sciences | Myfembree | $21 | 1 payment
|
| AbbVie | Oriahnn | $18 | 1 payment
|
| CooperSurgical | Paragard | $17 | 1 payment
|
| Mayne Pharma | None | $14 | 1 payment
|
2019: $109
| TherapeuticsMD | Imvexxy | $93 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $16 | 1 payment
|
Professional record
- NPI
- 1801963988
- Licence
- CA A82699California A82699: Current · expires 2027-01-31
- Trained
- Albert Einstein College of Medicine of Yeshiva University, 1999 · 27 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207VX0000X (207VX0000X); Federal specialty code 207VG0400X (207VG0400X)
- Mailing address
- 3838 California St, 316, San Francisco, CA, 94118
- NPI first listed
- 2006-11-30
- NPI last updated
- 2026-04-15
- NPI record certified
- 2026-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3838 California St, San Francisco, CA, 94118